German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.
ARTES Biotechnology and BioSun Pharmed will collaborate to develop and manufacture a human papilloma virus (HPV) vaccine in Iran, the companies announced on Nov. 4, 2016. ARTES specializes in cell-line and process development of virus like particle (VLP)-based vaccines and in technology transfer for pharmaceutically relevant production processes. BioSun Pharmed manufactures vaccines and biopharmaceutical products for the domestic Iran and international markets.
“This agreement is the next step in ARTES’ strategy to develop from a service provider for process development to a partner for full pharmaceutical product development,” said Michael Piontek, founder and managing director of ARTES Biotechnology, in the press release. For the first time, ARTES will be responsible for process development of API, formulation, quality control, and supply of preclinical test material. In addition, ARTES will be engaged in the design of the manufacturing site at BioSun and in the selection of third parties for GMP manufacturing.
Source: ARTES
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.